Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 5

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

Authors Pujals A, Favre L, Gaulard P, Wiels J

Received 19 February 2015

Accepted for publication 14 April 2015

Published 29 July 2015 Volume 2015:5 Pages 93—100


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor David Dingli

Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels4

1Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Créteil, 3Inserm U955, Institut Mondor de Recherche Biomédicale, 4UMR 8126 CNRS, Institut Gustave Roussy, Université Paris-Sud, Villejuif, France

*These authors contributed equally to this work

Abstract: The tumor suppressor TP53 is frequently mutated or inactivated in human cancers. Mutations of TP53 are less common in lymphomas than in other tumors, but the protein is often inhibited by the overexpression of its main regulator – MDM2. In the past 10 years, major efforts have been made to develop drugs that can reactivate p53 and restore its functions. This review focuses on recent advances in the development of small inhibitors of MDM2, which are potentially relevant for the treatment of B- and T-cell lymphomas. We will describe the current state of development of these drugs and discuss their mechanism of action in these hematological malignancies.

Keywords: lymphoma, p53, nutlin, apoptosis, MDM2

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]